Memantine — The NMDA Receptor Antagonist

Memantine acts as a low-affinity, voltage-dependent, uncompetitive antagonist at glutamatergic NMDA receptors. By binding to the NMDA receptor channel under conditions of excessive, prolonged glutamate release, it prevents the pathological influx of calcium ions that leads to excitotoxicity and neuronal cell death. Because of its low affinity and rapid off-rate, memantine preserves the physiological activation of NMDA receptors required for normal learning and memory processes, such as long-term potentiation (LTP). It also exhibits antagonistic activity at the serotonergic 5-HT3 receptor and nicotinic acetylcholine receptors.

Memantine is FDA-approved and extensively studied in humans for Alzheimer's disease, showing modest benefits in cognition, behavior, and activities of daily living in moderate to severe cases. However, there are no published human trials demonstrating efficacy for life extension or general cognitive enhancement in healthy, non-demented individuals. Its use in longevity is currently theoretical and extrapolated from its neuroprotective mechanisms in neurodegenerative disease models.

For Alzheimer's disease, the standard prescription dosage typically starts at 5 mg once daily, titrating up over several weeks to a target maintenance dose of 10 mg twice daily (or 28 mg once daily for extended-release formulations). As a prescription-only medication, its use for off-label neuroprotection or longevity purposes should be strictly supervised by a physician.

Memantine is generally well-tolerated, but common adverse effects include dizziness, headache, confusion, and constipation. It should be used with caution in patients with severe renal impairment, where dose adjustments are necessary, and in individuals with a history of seizure disorders. Concurrent use with other NMDA antagonists (e.g., amantadine, ketamine, dextromethorphan) should be avoided due to the risk of additive adverse effects.

Key Papers